Edward Kim is Professor of Radiology and Surgery at the Icahn School of Medicine at Mount Sinai in New York and Director, Interventional Oncology in the division of Interventional Radiology.  He is a globally recognized leader in the treatment of hepatocellular carcinoma with locoregional therapy alone or in combination with immune checkpoint inhibition, with a focus on radioembolization.  He has dozens of peer reviewed publications, lectures globally, serves on multiple advisory boards, and is on the board of directors for the Society of Interventional Oncology, as well as multiple committees for the Society of Interventional Radiology.

Dr Edward Kim has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Boston Scientific, Genentech/Roche, Eisai/Merck.